These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 23040257)
1. Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder. Sadeghi S; Garcia JA Semin Oncol; 2012 Oct; 39(5):608-14. PubMed ID: 23040257 [TBL] [Abstract][Full Text] [Related]
2. Urothelial cancers: using biology to improve outcomes. Pezaro C; Liew MS; Davis ID Expert Rev Anticancer Ther; 2012 Jan; 12(1):87-98. PubMed ID: 22149435 [TBL] [Abstract][Full Text] [Related]
3. Targeted agents in second-line bladder cancer therapy. Gerullis H; Otto T; Ecke TH Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698 [TBL] [Abstract][Full Text] [Related]
4. Molecular biology and targeted therapies for urothelial carcinoma. Seront E; Machiels JP Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962 [TBL] [Abstract][Full Text] [Related]
5. Systemic chemotherapy for urothelial transitional cell carcinoma: an overview of toxicity. Moulder SL; Roth BJ Semin Urol Oncol; 2001 Aug; 19(3):194-201. PubMed ID: 11561987 [TBL] [Abstract][Full Text] [Related]
9. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Aparicio AM; Elkhouiery AB; Quinn DI Urol Clin North Am; 2005 May; 32(2):217-30, vii. PubMed ID: 15862619 [TBL] [Abstract][Full Text] [Related]
10. Developing innovative strategies for advanced transitional cell carcinoma of the bladder. Pollera CF; Nelli F Expert Rev Anticancer Ther; 2006 Jan; 6(1):83-92. PubMed ID: 16375647 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report. Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990 [TBL] [Abstract][Full Text] [Related]
12. Overview of bladder cancer trials in the European Organization for Research and Treatment. de Wit R; Cancer; 2003 Apr; 97(8 Suppl):2120-6. PubMed ID: 12673705 [TBL] [Abstract][Full Text] [Related]
13. Systemic chemotherapy for advanced bladder cancer: update and controversies. Garcia JA; Dreicer R J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540 [TBL] [Abstract][Full Text] [Related]
14. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482 [TBL] [Abstract][Full Text] [Related]
15. Update on chemotherapy for advanced bladder cancer. Rosenberg JE; Carroll PR; Small EJ J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium. Vaughn DJ Cancer Treat Rev; 2008 Jun; 34(4):328-38. PubMed ID: 18262363 [TBL] [Abstract][Full Text] [Related]
18. Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Rosenberg JE Expert Rev Anticancer Ther; 2007 Dec; 7(12):1729-36. PubMed ID: 18062747 [TBL] [Abstract][Full Text] [Related]
19. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135 [TBL] [Abstract][Full Text] [Related]
20. Current status of chemotherapy for urothelial tract tumors. Sternberg CN; Scher HI Oncology (Williston Park); 1987 Jul; 1(5):41-50, 60. PubMed ID: 3079483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]